CPG
LGND icon

Cornerstone Planning Group’s Ligand Pharmaceuticals LGND Stock Holding History

Cornerstone Planning Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51
Closed -$5.39K – 1630
2025
Q1 		$5.39K Sell
51
-3
-6% -$339 ﹤0.01% 710
2024
Q4 		$6.33K Buy
54
+3
+6% +$339 ﹤0.01% 531
2024
Q3 		$5.89K Hold
51
– – ﹤0.01% 534
2024
Q2 		$5K Hold
51
– – ﹤0.01% 576
2024
Q1 		$3.77K Hold
51
– – ﹤0.01% 564
2023
Q4 		$3.64K Hold
51
– – ﹤0.01% 567
2023
Q3 		$3.06K Hold
51
– – ﹤0.01% 596
2023
Q2 		$3.68K Buy
+51
New +$3.83K ﹤0.01% 1006
2022
Q4 		$3.62K Buy
+51
New +$3.32K ﹤0.01% 1039

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cornerstone Planning Group's LGND Position: Q2 2025 in Review

Cornerstone Planning Group sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 51 shares — an estimated $5.39K sold.

Cornerstone Planning Group first reported a position in LGND in Q4 2022 and held it in 9 quarters. The position peaked at $6.33K in Q4 2024. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Cornerstone Planning Group reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cornerstone Planning Group sold 51 Ligand Pharmaceuticals shares in Q2 2025, an estimated $5.39K.
  • Cornerstone Planning Group first reported a position in Ligand Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Cornerstone Planning Group's Ligand Pharmaceuticals position peaked at $6.33K in Q4 2024.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Cornerstone Planning Group's 13F filing for Q2 2025, filed 11 Aug 2025.